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Abstract
Background: Use of gonadotropin-releasing hormone (GnRH) agonists has become popular for
virtually all stages of prostate cancer. We hypothesized that some men receive these agents after
only a limited work-up for their cancer. Such cases may be missed by tumor registries, leading to
underestimates of the total extent of GnRH agonist use.
Methods: We used linked Surveillance, Epidemiology and End-Results (SEER)-Medicare data from
1993 through 2001 to identify GnRH agonist use in men with either a diagnosis of prostate cancer
registered in SEER, or with a diagnosis of prostate cancer based only on Medicare claims (from the
5% control sample of Medicare beneficiaries residing in SEER areas without a registered diagnosis
of cancer). The proportion of incident GnRH agonist users without a registry diagnosis of prostate
cancer was calculated. Factors associated with lack of a registry diagnosis were examined in
multivariable analyses.
Results: Of incident GnRH agonist users, 8.9% had no diagnosis of prostate cancer registered in
SEER. In a multivariable logistic regression model, lack of a registry diagnosis of prostate cancer in
GnRH agonist users was significantly more likely with increasing comorbidity, whereas it was less
likely in men who had undergone either inpatient admission or procedures such as radical
prostatectomy, prostate biopsy, or transurethral resection of the prostate.
Conclusion: Reliance solely on tumor registry data may underestimate the rate of GnRH agonist
use in men with prostate cancer.
Background
Prostate cancer is the most frequently diagnosed non-skin
malignancy and is the third leading cause of cancer mor-
tality in men in the United States [1]. Use of androgen
deprivation therapy for prostate cancer in the form of
gonadotropin-releasing hormone (GnRH) agonists is
now common, with nearly half of men receiving it at
some point in their disease course [2]. Historically the use
of androgen deprivation therapy was limited to palliation
of metastatic prostate cancer. However, the 1990s wit-
nessed a dramatic increase in use of GnRH agonists for
prostate cancer across all stages and grades [3,4], even
though a survival benefit has only been demonstrated in
combination with radiation in the subset of patients with
locally advanced or high risk disease or following radical
prostatectomy in men with node-positive cancer [5-7].
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Coupled with its sizeable financial costs, the documented
adverse effects of GnRH agonist therapy – including oste-
oporosis, fractures, sexual dysfunction, reduced quality of
life and cardiovascular disease [8-12] – would argue for
conservative rather than widespread use, particularly in
settings where clear evidence of benefit is lacking.
Part of the popularity of GnRH agonist agents may be
their ease of administration, since they can be given as
once a month to every 3 or 4 month depot injections as an
outpatient. We believe that these agents are sometimes
prescribed without a complete evaluation for prostate
cancer, based on our clinical experience of encountering
patients treated on the basis of elevated prostate specific
antigen (PSA) levels alone. Such cases may be missed by
tumor registries, which mainly identify their cases from
inpatient evaluations, surgical procedures or histopatho-
logical reports [13]. Previous population based assess-
ments from tumor registry data in the Surveillance,
Epidemiology and End Results (SEER) program may
therefore underestimate the total extent of GnRH agonist
use [4].
A recent study demonstrated the advantage of supple-
menting tumor registry data with Medicare claims for can-
cer ascertainment [14]. We therefore used Medicare claims
from the linked SEER-Medicare database to identify men
receiving GnRH agonists who had prostate cancer on the
basis of claims data alone, but who were not registered as
having a diagnosis of prostate cancer in SEER. We then
examined the factors associated with lack of a SEER diag-
nosis of prostate cancer in men receiving GnRH agonists.
We hypothesized that older age, comorbidity and black
race would be associated with GnRH agonist use in the
setting of no prostate cancer diagnosis in SEER, because
previous studies have shown those characteristics to be
associated with incomplete diagnostic evaluation for can-
cer [14-16].
Methods
Data Sources
This study used data from the linked SEER-Medicare data-
base. The SEER program consists of a group of popula-
tion-based tumor registries in selected geographic areas,
from 11 states, covering approximately 14% of the United
States population [17,18]. Medicare is a federal program
that covers health services for 97% of persons aged 65
years and older. It provides data in the form of claims sub-
mitted by providers for reimbursement, which include
information on diagnoses and the service, testing or pro-
cedure carried out. Data from the two programs have been
linked to yield a database containing information on per-
sons aged 65 and older with incident cancers. In addition
to containing information on patients with incident can-
cers identified through the SEER program, the linked data-
base also includes as a "non-cancer control" group a 5%
random sample of Medicare eligible patients residing in
the SEER areas who do not have a registered diagnosis of
cancer by one of the SEER tumor registries. The version of
the SEER-Medicare database used for this study contains
Medicare claims through 2001 and SEER cancer cases
through 1999.
Study Subjects
The analysis was limited to men who received GnRH ago-
nists for incident prostate cancer. Since we hypothesized
that the factors affecting whether patients were registered
in a SEER tumor registry pertained to the initial diagnostic
evaluation of the cancer, only men receiving GnRH ago-
nists within a year of diagnosis were included in the anal-
yses.
The "SEER group" included men aged 67 years and older
with incident prostate cancer registered in a SEER tumor
registry from 1993 to 1999 who received at least one dose
of a GnRH agonist within a year of cancer diagnosis
(restricting the analysis to men receiving at least six doses
did not substantially alter the results). The analysis was
limited to men 67 years and older to allow assessment of
Medicare claims data for at least two years prior to the
diagnosis of cancer. To ensure completeness of Medicare
claims data, men diagnosed by autopsy, death certificate,
or not covered under both Medicare Part A and B, or were
in an HMO any time from 2 years before to 1 year after
their cancer diagnosis were excluded.
The "non-SEER group" included men in the 5% control
group (who therefore did not have a diagnosis of prostate
cancer registered in a SEER tumor registry) who had a first
primary diagnosis of prostate cancer from Medicare inpa-
tient, outpatient or physician claims from 1993 through
1999 (claims were searched from 1991) and received at
least one dose of a GnRH agonist following the diagnosis
(509 men were initially identified, after exclusion of 16
GnRH agonist users who did not have a claims diagnosis
of prostate cancer). To ensure that the GnRH agonist use
was for incident prostate cancer, men who had a claims
diagnosis for a history of prostate cancer, who had their
first dose of GnRH agonist more than one year after the
date of the first claim diagnosis of prostate cancer, or who
had any claims for GnRH agonist use prior to the first
claims diagnosis of prostate cancer, were excluded (238
cases). Furthermore, as for the SEER group, the analysis
was limited to men aged 67 years and older, and men not
covered under both Medicare Part A and B, or who were
in an HMO any time from 2 years before to 1 year after
their cancer diagnosis were excluded (71 cases). Since our
hypothesis was that these patients were not registered in
SEER due to a less complete diagnostic work-up, we
wanted to exclude patients with prostate cancer that mayBMC Health Services Research 2008, 8:146 http://www.biomedcentral.com/1472-6963/8/146
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have failed to be registered in SEER purely due to method-
ological issues relating to reporting to SEER or with the
SEER to Medicare linkage process. These issues include the
possibility that: 1) men in the non-SEER group may have
not been living in a SEER area at the time of their prostate
cancer diagnosis, 2) men in the non-SEER group may have
received their prostate cancer care entirely outside of a
SEER area, despite being resident in a SEER area at the
time of their diagnosis 3) there was a delay in reporting of
the diagnosis to SEER, 4) the linkage process between
Medicare and SEER files failed in some cases. Men living
outside of a SEER area at the time of their prostate cancer
diagnosis were identified from county code information
available from Medicare, and excluded (77 cases). Men
whose only hospital visits (either from inpatient or outpa-
tient Medicare claims) for prostate cancer within a year of
diagnosis occurred at a hospital located outside of their
SEER state of residence were excluded (10 cases). The
probabilities of a delay in reporting of the diagnosis to
SEER and an imperfect linkage of SEER to Medicare data
were modeled, and used to exclude men for each calendar
year (21 and 7 cases, respectively). Details for these mod-
els are provided in the Statistical Methods section, below.
Study Variables
A diagnosis of prostate cancer was identified directly from
the SEER files for men who were registered in a SEER
tumor registry. For the non-SEER group, a prostate cancer
diagnosis was based on the presence of the relevant Inter-
national classification of diseases, 9th revision, (ICD-9)
code (Table 1) in the first position in any inpatient, out-
patient or physician Medicare claim. For both SEER and
non-SEER groups, Medicare claims for the relevant ICD-9
procedure and Current Procedural Terminology, 4th edi-
tion (CPT-4) codes were used to identify related proce-
dures including radical prostatectomy, radiation
treatment, transurethral resection of the prostate (TURP),
pelvic computed tomographic (CT) scanning or magnetic
resonance imaging (MRI) and bone scans (Table 1).
GnRH agonist administration was identified through spe-
cific Medicare claims codes used to designate each dose
given of certain specific injectable medications, as
described previously [4].
Patient demographic characteristics were derived from the
SEER (for region of residence at time of diagnosis) and
Medicare records in the linked database. The socio-eco-
nomic characteristics of each patient were based on per-
cent of adults with less than 12 years of education from
census tract data. Comorbidity was assessed using
Klabunde's modification of the Charlson comorbidity
index, based on information from Medicare inpatient,
outpatient and physician claims in the 12 months prior to
cancer diagnosis [19].
Statistical Methods
Probabilities for reporting delay and imperfect SEER to Medicare 
linkage
We developed a model to estimate the probability that an
individual patient in the non-SEER group had no prostate
cancer diagnosis in SEER due to a delay in reporting of the
diagnosis. Using two sets of public use SEER data reported
with a lag time of three years apart, for patients diagnosed
with prostate cancer from 1973–1996 (available in April
1999 [20]) and an updated dataset available in April 2002
[21], we built a multiple logistic regression model to pre-
dict the likelihood of a three year delay. For patients not
listed in the earlier dataset, delay was defined as the pres-
ence in the later dataset of a diagnosis of cancer in 1996
or earlier. Predictor variables included age, race, SEER
Table 1: Claims definition of study variables
Study Variablea Claims Definition
Prostate cancer diagnosis ICD-9 diagnosis code 185.xx in first position
History of prostate cancer ICD-9 diagnosis code V10.46
Radical Prostatectomy Any of:ICD-9 procedure code 60.5 or CPT-4 codes 
55801,55810,55812,55815,55821,55831,55842,55845
Radiation Treatment Any of: ICD-9 procedure code 92.2× or ICD-9 diagnosis codes V58.0, 
V66.1, V67.1 or CPT-4 codes 77621–77499, 77600–77620, 77750–77799, 
79200–79999 or Revenue codes 330, 333, 339, 342
Prostate Biopsy Any of: ICD-9 procedure codes 60.1 or CPT codes 55700–55705
Transurethral resection of prostate Any of: ICD-9 procedure code 60.2 or CPT-4 codes 52612, 52614, 52647, 
52468
Transrectal ultrasound Any of: CPT-4 codes 76872, 76873
Pelvic computed tomographic scanning or magnetic resonance imaging Any of: ICD-9 procedure codes 88.01, 88.95 or CPT-4 codes 72192–
72194, 74150, 74160, 74170–74175, 72195–72197, Health Care Common 
Procedure Code A9507
Bone Scan Any of: ICD-9 procedure code 92.14, CPT-4 codes 78300, 78305, 78306, 
78315, 78320
ICD-9, International Classification of Diseases, 9th revision; CPT-4, Current Procedural Terminology, 4th edition
aA diagnosis or procedure was deemed to be present if it was listed at least once in any of the outpatient, inpatient or provider Medicare claims filesBMC Health Services Research 2008, 8:146 http://www.biomedcentral.com/1472-6963/8/146
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region, reporting source (based on presence or absence of
an inpatient admission relating to prostate cancer) and
histologic confirmation of diagnosis (based on presence
or absence of a surgical procedure on the prostate). To
account for the probability of delay, pyr, for periods differ-
ent from three years, the results were further adjusted
using data from a previous study listing the rate of incom-
plete records for prostate cancer diagnosis in SEER as a
function of different lengths of reporting lag time [22].
The overall probability of delay, pi, for each individual
patient, on the basis of patient characterstics, βX, was
therefore calculated using the formula listed:
pi = EXP(LOG (pyr/(1-pyr)) + βX)/(1 + EXP(LOG (pyr/(1-
pyr)) + βX)).
We estimated the probability of an individual patient
lacking a diagnosis in SEER due to an imperfect linkage
between Medicare and SEER by applying known SEER to
Medicare match rates for prostate cancer (available from
the National Cancer Institute) stratified by age, race and
SEER region. In this adjustment process, we assumed no
interactions between age, race and SEER region on the
match rate.
By applying the individual probabilities of a delay, and an
imperfect SEER to Medicare linkage, each patient was
assigned a weighted value from 0 to 1 (with a patient
receiving 0 if there was a 100% probability that they were
not registered in SEER due to a delay or imperfect linkage,
and a patient receiving 1 having a zero probability). Sub-
tracting the sum of the weighted values from the total
number of patients yielded the number of patients
excluded due to the possibility of a reporting delay or an
imperfect linkage.
Analyses
The number of men in the 5% control group identified as
having prostate cancer by Medicare claims and receiving a
GnRH agonist within one year of diagnosis (i.e., the non-
SEER group) was inflated by a factor of 20. The proportion
of incident GnRH agonist users that were in the non-SEER
group was then calculated (with bootstrap methods used
to estimate 95% confidence intervals) and stratified by
year of diagnosis, age, race, SEER region, census tract edu-
cation, and comorbidity. Chi-square testing was used to
compare proportions across categories within each stra-
tum. The proportion of incident GnRH agonist users who
underwent hospitalization, diagnostic work-up (prostate
biopsy, transrectal ultrasound), surgical procedures
(TURP, radical prostatectomy), radiation treatment, or
staging (CT scan or MRI, bone scan) within 3 months
before or after diagnosis (date based on first Medicare
claim for prostate cancer) was compared between men in
the SEER and non-SEER groups using the chi-square test.
Multivariable logistic regression was performed to further
assess the factors associated with lack of a SEER diagnosis
of prostate cancer among incident GnRH agonist users. In
the regression models, lack of a SEER diagnosis of prostate
cancer was treated as the dependent variable and poten-
tially relevant study variables described above were
entered as independent variables. Odds ratios (ORs) with
95% confidence intervals (CI) were calculated for each
covariate. All tests of statistical significance were two-
sided, with p < 0.05 being considered significant. All anal-
yses were performed using SAS version 9.1 (SAS Institute,
Cary, NC). The study protocol was approved by the Insti-
tutional Review Board of the University of Texas Medical
Branch at Galveston.
Results
A total of 17,424 men identified with incident prostate
cancer in the SEER tumor registries from 1993 through
1999 received a GnRH agonist within a year of diagnosis.
During the same period, a total of 85 men were identified
from the 5% "non-cancer control" sample as having a
Medicare claims diagnosis of incident prostate cancer and
receiving a GnRH agonist within a year of diagnosis after
excluding men that may not have been registered in SEER
due to methodologic issues. Inflating this number by a
factor of 20 to account for the 5% sampling yielded an
estimate of 1700 men with prostate cancer diagnosed by
Medicare claims but not registered in the SEER program
who received GnRH agonists within a year of diagnosis.
Table 2 presents patient characteristics of the incident
GnRH agonist users, divided as SEER group versus non-
SEER group. Overall, 8.9% (95%CI: 7.8%–10.1%) did not
have a prostate cancer diagnosis registered in the SEER
program. A higher proportion of men 75 years and older,
black, and with comorbidities had no prostate cancer
diagnosis registered in the SEER program, but differences
in proportions were statistically significant only for
comorbidity.
Table 3 shows the proportion of incident GnRH agonist
users with various diagnoses and procedures within 3
months before or after diagnosis of prostate cancer, com-
paring those with a diagnosis of prostate cancer from a
SEER tumor registry versus those with a diagnosis based
only on Medicare claims. Men in the non-SEER group
were less likely to undergo either inpatient admission or a
procedure that would lead to diagnosis or histologic con-
firmation of prostate cancer (TURP, prostate biopsy, tran-
srectal ultrasound or radical prostatectomy), with 87.0%
in the SEER group versus 70.8% in the non-SEER group
undergoing at least one of the above (p < 0.01 for differ-
ence in proportions). Men in the non-SEER group had
lower rates of staging work-up (bone scan or CT scan/
MRI) but the differences did not achieve statistical signif-BMC Health Services Research 2008, 8:146 http://www.biomedcentral.com/1472-6963/8/146
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icance. They were also significantly more likely to be
treated with GnRH agonists without concurrent radiation
treatment.
Table 4 presents the results of two multivariable logistic
regression models examining factors predicting lack of a
prostate cancer diagnosis in a SEER tumor registry among
incident GnRH agonist users. Model 1 includes patient
characteristics from Table 2 entered as independent varia-
bles. Model 2 additionally includes diagnostic procedures
from Table 3 entered as independent variables. In the first
model, greater comorbidity significantly increased the
likelihood that an incident GnRH agonist user did not
have a diagnosis of prostate cancer listed in the SEER pro-
gram. There were also significant, two-fold variations by
SEER geographic region. In the second model, receipt of
TURP or use of radiation treatment were associated with a
lower likelihood that an incident GnRH agonist user
lacked a diagnosis of prostate cancer in the SEER program.
We also performed a third model (not shown) entering
the composite variable from Table 3 of receipt of at least
one of: hospitalization, TURP, transrectal ultrasound, rad-
ical prostatectomy or prostate biopsy. This was associated
with a significantly reduced likelihood that an incident
GnRH agonist user was not registered in the SEER pro-
gram (OR 0.38; 95%C.I. 0.22–0.65).
Discussion
The results of our study can be summarized as follows.
Reliance solely on cases of prostate cancer registered in the
SEER program appears to underestimate incident GnRH
agonist use by about 9%, even after accounting for meth-
odologic issues that may have affected registration or
reporting. Among incident GnRH agonist users, lack of a
diagnosis of prostate cancer in the SEER program was
more likely in men with comorbidities whereas it was less
Table 2: Patient characteristics of incident GnRH agonist users
Incident GnRH agonist users
Characteristics Strata SEER groupa Non-SEER groupb Proportion not in SEER group
nn c %p - v a l u e d
Total 17424 1700 8.9
Year of diagnosis 1993 2008 190 8.6 0.26
1994 1983 269 11.9
1995 2034 178 8.0
1996 2330 265 10.2
1997 2750 215 7.3
1998 2964 260 8.1
1999 3355 323 8.8
Age at diagnosis (years) 67 – 74 8209 653 7.4 0.11
≥75 9215 1047 10.2
Race White 14484 1395 8.8 0.70
Black 1626 199 10.9
Other/Unknown 1314 106 7.5
Region Northeast 2570 265 9.3 0.15
Midwest 5597 351 5.9
South 1331 156 10.5
West 7926 928 10.5
Zip education < 12.5% 4223 294 6.5 0.65
(% adult <12 years education) ≥12.5% 12090 966 7.4
Comorbidity Index 0 12604 1045 7.7 0.03
≥14 8 2 0 6 5 5 1 2 . 0
aDiagnosis of prostate cancer registered in SEER
bDiagnosis of prostate cancer from Medicare claims, but not in SEER, and excluding men who may have had a delay in reporting, moved out of the 
SEER area at the time of diagnosis or failed the SEER to Medicare linkage
cSample size inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
dChi-square test for comparison of proportions across strata for each characteristic, based on uninflated sample sizes. P-value reported for year of 
diagnosis is based on test for linear trend
GnRH; Gonadotropin-releasing hormone
SEER; Surveillance, Epidemiology and End-ResultsBMC Health Services Research 2008, 8:146 http://www.biomedcentral.com/1472-6963/8/146
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likely for men who had undergone procedures such as
TURP, prostate biopsy, or radiation treatment.
Based on the results of this study, what can be inferred
about GnRH agonist users without a tumor registry diag-
nosis of prostate cancer? They tend to be older, of black
race, and have more comorbidities, all typical of patient
characteristics associated with less complete diagnostic
evaluations for cancer [14,15]. GnRH agonist users with-
out a diagnosis in SEER had lower rates of procedures
which allow histologic confirmation of the diagnosis, an
important element for cancer registration, as compared to
those registered in SEER (Table 3) [15]. Nevertheless, two
thirds of men in the non-SEER group underwent prostate
biopsy within 3 months of their claims diagnosis of pros-
tate cancer. This may suggest that even with an available
histologic diagnosis, registration in SEER is further facili-
tated when there is an inpatient admission, or surgical
procedure such as radical prostatectomy, which were both
somewhat more common in the SEER group. Alterna-
tively, the results of the prostate biopsies noted in the
non-SEER group may have either been negative or equiv-
ocal. Follow-up PSA testing is common following a nega-
tive prostate biopsy, and a rising level may have
potentially led to treatment with GnRH agonists in the
absence of a definitive histologic diagnosis [23].
Given the nature of cancer registration, prostate cancer
cases managed with surgery or radiation are most likely to
be captured due to the frequent hospital contacts (either
through inpatient admission or visits to hospital outpa-
tient departments). In contrast, men treated with GnRH
agonists alone may frequently be managed entirely with
physician office visits. The finding that a proportion of
GnRH agonist users with prostate cancer are missed by the
SEER registries is therefore not surprising. Nevertheless, if
the proportion of GnRH agonist users without a SEER reg-
istry diagnosis is extrapolated to national figures (with
40% of the over 200,000 new prostate cancer cases in the
United States receiving GnRH agonists), it could translate
to several thousand men a year [1,4]. It is especially
important to be able to monitor use of GnRH agonists in
men with prostate cancer given limited evidence of effi-
cacy, particularly in men with substantial comorbidity,
and the increasing recognition of life threatening adverse
effects such as bone fracture and cardiovascular disease
[11,12,24-27].
There are limitations to our study. First, we made an
assumption that the distribution of subject characteristics
in the 5% control sample could be extrapolated to the
entire non-cancer population, inflating the sample size by
a factor of 20. This assumption might not hold true, par-
ticularly with extensive stratification. We therefore mini-
mized the number of strata within each characteristic.
Second, the sample size was small, limiting the statistical
power to draw inferences about factors affecting registra-
tion in SEER among GnRH agonist users. Third, in order
to ensure that demographic information was comparable
between the SEER and non-SEER groups, we were limited
Table 3: Diagnoses and procedures in incident GnRH agonist users, comparing those with and without a diagnosis of prostate cancer in 
the SEER tumor registries
Diagnoses and procedures in incident GnRH agonist usersa
SEER groupb Non-SEER groupc
n% n d %p - v a l u e e
Procedures related to diagnosis and histologic confirmation of prostate cancera
Hospitalization 3691 21.2 338 19.9 0.75
Transurethral resection of prostate 1504 8.7 56 3.3 0.08
Prostate Biopsy 13728 79.0 1153 67.8 0.01
Transrectal Ultrasound 10342 59.5 868 51.1 0.11
Radical Prostatectomy 766 4.4 51 3.0 0.47
Any of the above 15122 87.0 1204 70.8 <0.01
Other treatment/work-upa
Radiation Therapy 3156 18.2 85 5.0 <0.01
CT scan/MRI pelvis 6421 36.9 503 29.6 0.16
Bone Scan 11048 63.6 910 53.5 0.06
aWithin 3 months before or after diagnosis of prostate cancer (date based on Medicare claims)
bDiagnosis of prostate cancer registered in SEER
cDiagnosis of prostate cancer from Medicare claims, but not in SEER and excluding men who may have had a delay in reporting, moved out of the 
SEER area at the time of diagnosis or failed the SEER to Medicare linkage
dSample sizes inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
eChi-square test for comparison of proportions between SEER and non-SEER group, based on uninflated sample sizes
GnRH; Gonadotropin-releasing hormone
SEER; Surveillance, Epidemiology and End-ResultsBMC Health Services Research 2008, 8:146 http://www.biomedcentral.com/1472-6963/8/146
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to Medicare as the source for both. Medicare claims do not
allow for direct assessment of marital status, a potentially
important predictor of cancer work-up [28], and are of
limited utility in identifying race/ethnicity categories
other than White or Black [29]. In addition, there may be
error introduced in the assessment of some of the varia-
bles using Medicare claims. However, we used previously
validated methods for important variables such as comor-
bidity and GnRH agonist use [19,30]. Furthermore, since
we used similar methods of assessment for both the SEER
and non-SEER groups, any misclassification as a result of
using claims data would tend to bias the results towards
the null, such that the significant associations noted in
Table 4 would still be valid. Fourth, despite the multiple
methodologic exclusions we imposed, the 8.9% figure for
incident GnRH agonist users that are not captured by the
SEER registries is likely to be an overestimate. For exam-
ple, in the non-SEER group, some cases classified as inci-
dent GnRH agonist use may in fact have been prevalent
use, due to the difficulty in defining date of cancer diagno-
sis with Medicare claims alone. To estimate the impact of
this, we applied the Medicare claims algorithm to SEER
GnRH agonist users (who have an accurate date of diagno-
sis provided by the registry), finding that 90.4% were cor-
rectly classified as incident use. In addition, we were only
able to exclude men with hospital-based prostate cancer
care provided outside of the SEER state of residence, since
information on location was only available for hospitals.
Table 4: Predictors of lack of a diagnosis of prostate cancer in the SEER tumor registries among incident GnRH agonist users
Model 1a Model 2b
Variable Category Distribution (%) Odds Ratio 95% CI Odds Ratio 95% CI
Year of diagnosis 1993 11.5 1.00 1.00
1994 11.8 1.35 (0.59,3.10) 1.34 (0.58,3.09)
1995 11.6 0.88 (0.35,2.19) 0.88 (0.35,2.20)
1996 13.6 1.13 (0.49,2.61) 1.14 (0.49,2.65)
1997 15.5 0.78 (0.33,1.88) 0.81 (0.34,1.95)
1998 16.9 0.85 (0.37,1.98) 0.89 (0.38,2.07)
1999 19.2 0.91 (0.41,2.04) 0.96 (0.43,2.17)
Age at diagnosis (years) 67 – 74 46.3 1.00 1.00
≥75 53.7 1.38 (0.89,2.15) 1.24 (0.79,1.95)
Ethnicity White 83.0 1.00 1.00
Black 9.6 1.30 (0.66,2.58) 1.23 (0.62,2.46)
Other 7.4 0.67 (0.27,1.65) 0.68 (0.28,1.68)
Region West 46.3 1.00 1.00
Northeast 14.8 0.86 (0.46,1.60) 0.84 (0.45,1.57)
Midwest 31.1 0.51 (0.29,0.91) 0.46 (0.26,0.83)
South 7.8 0.78 (0.36,1.71) 0.79 (0.36,1.72)
Comorbidity Index 0 71.4 1.00 1.00
≥1 28.6 1.60 (1.03,2.48) 1.55 (1.00,2.41)
Zip education < 12.5% 25.7 1.00 1.00
(% adult < 12 years education) ≥12.5% 74.3 1.24 (0.68,2.28) 1.24 (0.68,2.26)
Procedures within 3 months before or after diagnosis
Hospitalization 21.2 1.48 (0.79,2.79)
Transurethral resection of prostate 8.4 0.19 (0.05,0.68)
Prostate Biopsy 77.9 0.59 (0.33,1.06)
Transrectal Ultrasound 58.7 0.96 (0.57,1.62)
Radical Prostatectomy 4.5 0.51 (0.13,2.00)
Radiation Therapy 17.1 0.27 (0.10,0.72)
CT scan/MRI pelvis 36.3 1.08 (0.63,1.85)
Bone scan 62.6 0.86 (0.52,1.44)
aMultivariable logistic regression model with presence or absence of a diagnosis of prostate cancer in SEER as the dependent variable, and year of 
diagnosis, patient age, race, SEER region of residence, comorbidity index, and educational status entered as independent variables
bMultivariable logistic regression model with presence or absence of a diagnosis of prostate cancer in SEER as the dependent variable, and the 
variables from Model 1 with the addition of the listed diagnostic procedures entered as independent variables
GnRH; Gonadotropin-releasing hormone
SEER; Surveillance, Epidemiology and End-ResultsBMC Health Services Research 2008, 8:146 http://www.biomedcentral.com/1472-6963/8/146
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Finally, only subjects age 67 or older with Medicare Part A
and B enrollment but without HMO membership were
studied, so the results may not necessarily apply to
younger men or patients with other forms of health insur-
ance.
Conclusion
Reliance solely on data from tumor registries may under-
estimate the rate of GnRH agonist use in men with pros-
tate cancer.
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